New drug duo takes on tough cancers
NCT ID NCT06848699
First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced solid tumors, including lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults who have not responded to other treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Provincial Cancer Hospital
RECRUITINGHunan, Changsha, 410031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Second Affiliated Hospital of Army Medical University, PLA
RECRUITINGChongqing, 400000, China
Contact
-
Shandong Cancer Hospital
RECRUITINGJinan, Shangdong, China
Conditions
Explore the condition pages connected to this study.